The therapeutic approaches for hepatitis C virus: Protease inhibitors and polymerase inhibitors

Gut and Liver

Volumn 5, Issue 4, 2011, Pages 406-417

  Kwo, Paul Y ^a   Vinayek, Rakesh ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis C virus; Polymerase inhibitor; Protease inhibitor

Indexed keywords

A 832; ACH 806; ANTIVIRUS AGENT; AZD 7295; BALAPIRAVIR; BI 201335; BMS 790052; BOCEPREVIR; CILUPREVIR; DANOPREVIR; ERYTHROPOIETIN; FILIBUVIR; IDX 184; MERICITABINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PLACEBO; PSI 7851; RIBAVIRIN; RITONAVIR; SERINE PROTEINASE INHIBITOR; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VANIPREVIR; VIRUS RNA;

ANEMIA; CARDIOTOXICITY; CHILL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAUNDICE; LIVER TOXICITY; MONOTHERAPY; NEPHROTOXICITY; PRURITUS; RASH; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REPLICATION;

EID: 81855220325     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2011.5.4.406     Document Type: Review

References (46)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52. (Pubitemid 32634271)
2. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000;81(Pt 7):1631-1648. (Pubitemid 30427068)
3. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127:1347-1355. (Pubitemid 39457761)
4. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640-648. (Pubitemid 47436108)
5. Zeuzem S. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients. J Hepatol 2008;49:157-159.
6. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.
7. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850.
8. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-1303.
9. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006;50:1013-1020. (Pubitemid 43327807)
10. Friedrich-Rust M, Forestier N, Sarrazin C, Reesink HW, Herrmann E, Zeuzem S. Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection. Ultrasound Med Biol 2007;33:1362-1367. (Pubitemid 47302190)
11. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341.
12. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-716.
13. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
14. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
15. Forestier N, Larrey D, Guyader D, et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 2011;54:1130-1136.
16. Gane EJ, Roberts SK, Stedman C, et al. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. J Hepatol 2010;50(Suppl 1):S380.
17. Gane E, Rouzier R, Stedman C, et al. Ritonavir boosting of low dose RG7227/ITMN-191, HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens. J Hepatol 2010;52(Suppl 1):S16-S17.
18. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010;138:913-921.
19. Marcellin P, Reesink H, Berg T, et al. Antiviral activity and safety of TMC435 combined with peginterferon alpha-2a and ribavirin in patients with genotype 1 hepatitis C infection who failed previous IFN-based therapy. J Hepatol 2009;50(Suppl 1):S385.
20. Sulkowski MS, Ferenci P, Emanoil C, et al. SILEN-C1: early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV infection. Hepatology 2009;50(Suppl 4):90A.
21. Sulkowski M, Bourliere M, Bronowicki JP, et al. SILEN-C2: early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (PEGIFN/RBV) in chronic HCV genotype-1 patients with non-response to PEGIFN/RBV. J Hepatol 2010;52(Suppl 1):S462-S463.
22. Betzi S, Eydoux C, Bussetta C, et al. Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step. Antiviral Res 2009;84:48-59.
23. Kim MS, Park C, Lee JH, Myung H. Selection and target-site mapping of peptides inhibiting HCV NS5B polymerase using phage display. J Microbiol Biotechnol 2008;18:328-333.
24. Martin Hernando JI, Ontoria JM, Malancona S, et al. Optimization of thienopyrrole-based finger-loop inhibitors of the hepatitis C virus NS5B polymerase. ChemMedChem 2009;4:1695-1713.
25. McGowan D, Nyanguile O, Cummings MD, et al. 1,5-Benzodiazepine inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett 2009;19:2492-2496.
26. Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007;46(Suppl 1):862A.
27. Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days. J Hepatol 2008;48(Suppl 2):S29.
28. Gane EJ, Rodriguez-Torres M, Nelson DE, et al. Sustained virologic response (SVR) following RG7128 1500mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders. J Hepatol 2010;52(Suppl 1):S16.
29. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-1475.
30. Lalezari J, Asmuth D, Casiró A, et al. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. Hepatology 2009;50(Suppl 4):228A.
31. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PEGIFN/RBV in a phase 2B trial: rapid virologic suppression in treatment-naïve patients with HCV GT2/GT3. J Hepatol 2011;54(Suppl 1):S28.
32. Larrey D, Benhamou Y, Lohse AW, et al. Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J Hepatol 2009;50(Suppl 1):S383-S384.
33. Brainard DM, Anderson MS, Petry A, et al. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281, in treatment-naïve genotype 1A, 1B and 3 HCV-infected patients. Hepatology 2009;50(Suppl 4):263A.
34. Erhardt A, Wedemeyer H, Benhamou Y, et al. Safety, pharmacokinetics and antiviral effect of BILB1941, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J Hepatol 2007;46(Suppl 1):S222.
35. Jacobson I, Pockros P, Lalezari J, et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment naïve patients chronically infected with HCV genotype 1. J Hepatol 2009;50(Suppl 1):S382-S383.
36. Rodriguez-Torres M, Lawitz E, Conway B, et al. Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naïve genotype 1 HCV-infected patients. J Hepatol 2010;52(Suppl 1):S14.
37. Lawitz E, Rodriquez-Torres M, Rustgi VK, et al. Safety and antiviral activity of ana598 in combination with pegylated interferon alpha2a plus ribavirin in treatment-naïve genotype-1 chronic HCV patients. J Hepatol 2010;52(Suppl 1):S467.
38. Good SS, Bu C, Camire M, et al. Preclinical pharmacokinetic and safety profile of IDX375, a novel and potent nonnucleoside HCV polymerase inhibitor. J Hepatol 2009;50(Suppl 1):S125-S126.
39. Rodriguez-Torres M, Lawitz E, Cohen D, et al. Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone. Hepatology 2009;50(Suppl 4):91A.
40. Bavisotto L, Wang CC, Jacobson IM, et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor in a phase-1 trial in HCV genotype 1 infected subjects. Hepatology 2007;46(Suppl 1):255A.
41. Shih I, Vliegen I, Peng B, et al. Mechanistic characterization of GS-9190, a novel non-nucleoside inhibitor of HCV NS5B polymerase with potent antiviral activity and a unique mechanism of action. Hepatology 2007;46(Suppl 1):859A.
42. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100.
43. Nettles R, Chien C, Chung E, et al. BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology 2008;48(Suppl 1):1025A.
44. Pol S, Everson G, Ghalib R, et al. Once-daily NS5A inhibitor (BMS-790052) plus peginterferon-alpha-2a and ribavirin produces high rates of extended rapid virologic response in treatment-naïve HCV-genotype 1 subjects: phase 2a trial. J Hepatol 2010;52(Suppl 1):S462.
45. Gane E, Foster GR, Cianciara J, et al. Antiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients. J Hepatol 2010;52(Suppl 1):S464.
46. Colonno R, Peng E, Bencsik M, et al. Identification and characterization of PPI-461, a potent and selective HCV NS5A inhibitor with activity against all HCV genotypes. J Hepatol 2010;52(Suppl 1):S14-S15.